68535-56-8

Basic information

• Product Name: 4-(OXAZOL-2-YL)PHENOL
• Synonyms: 4-(OXAZOL-2-YL)PHENOL;4-(2-oxazolyl)Phenol
• CAS NO: 68535-56-8
• Molecular Formula: C₉H₇NO₂
• Molecular Weight: 161.16
• Mol File: 68535-56-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(OXAZOL-2-YL)PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(OXAZOL-2-YL)PHENOL(68535-56-8)
• EPA Substance Registry System: 4-(OXAZOL-2-YL)PHENOL(68535-56-8)

Safety Data

• Hazardous Substances Data: 68535-56-8(Hazardous Substances Data)

Usage

General Description

4-(oxazol-2-yl)phenol is a chemical compound with the molecular formula C8H6N2O2. It is a derivative of phenol, with an oxazole ring attached to the benzene ring. 4-(OXAZOL-2-YL)PHENOL has been studied for its potential pharmaceutical properties, including anti-inflammatory and antioxidant effects. It is also used in the synthesis of other organic compounds and can be found in various reactions and processes in organic chemistry. 4-(oxazol-2-yl)phenol has potential applications in the development of new drugs and in various fields of organic chemistry research.

Upstream product

• 156780-52-8 2-(4-methoxyphenyl)-1,3-oxazole 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 481053-48-9 4-(oxazol-2-yl)phenyl methanesulfonate 
• 943767-42-8 4-(2-oxazolyl)phenyl acetate 
• 62882-11-5 4-(1,3-oxazol-2-yl)aniline 

Downstream Products

• 943767-52-0 2-[4-(4-nitrophenoxy)phenyl]oxazole 
• 943767-53-1 4-[4-(2-oxazolyl)phenoxy]benzenamine 
• 108-95-2 phenol 
• 102974-05-0 2-{p-[3-(3,4-Dimethoxyphenethylamino)-2-hydroxypropoxy]phenyl}oxazole 

Relevant articles and documents

VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.

3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: Design, synthesis and 3D-QSAR studies

Carbamates are a well-established class of fatty acid amide hydrolase (FAAH) inhibitors. Here we describe the synthesis of meta-substituted phenolic N-alkyl/aryl carbamates and their in vitro FAAH inhibitory activities. The most potent compound, 3-(oxazol-2yl)phenyl cyclohexylcarbamate (2a), inhibited FAAH with a sub-nanomolar IC50 value (IC50=0.74 nM). Additionally, we developed and validated three-dimensional quantitative structure-activity relationships (QSAR) models of FAAH inhibition combining the newly disclosed carbamates with our previously published inhibitors to give a total set of 99 compounds. Prior to 3D-QSAR modeling, the degree of correlation between FAAH inhibition and in silico reactivity was also established. Both 3D-QSAR methods used, CoMSIA and GRID/GOLPE, produced statistically significant models with coefficient of correlation for external prediction (R2 PRED) values of 0.732 and 0.760, respectively. These models could be of high value in further FAAH inhibitor design.

Discovery of novel and potent aryl diamines as leukotriene A4 hydrolase inhibitors

The synthesis and biological evaluation of a series of aryl diamines as inhibitors of LTA4-h inhibitors are described. The optimization which led to the identification of the optimal para-substitution on the diphenyl ether moiety and diamine spacer is discussed. The resulting compounds such as 3l have excellent enzyme and cellular potency as well as desirable pharmacokinetic properties.

Diamine derivatives as inhibitors of leukotriene A4 hydrolase

This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9

BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION

The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: An example is

Di-heterocyclic compounds and their use as antiviral agents

Compounds of the formulas: STR1 wherein Het is an oxazole or oxazine moiety; X is O, S or SO, n is an integer from 3 to 9, Y is an aliphatic bridge; and the various R groups represent hydrogen or various substituents as described herein, are useful as antiviral agents, especially against picornaviruses. N-(Chloroalkyl)amide intermediates for the compounds of Formula I are also active as antiviral agents. Related compounds outside the scope of the above formulas are also disclosed.

Synthesis and analgesic-antiinflammatory activity of some 4- and 5-substituted heteroarylsalicylic acids

We have made a series of 4- and 5-aryl- and 4- and 5-heteroarylsalicylic acid derivatives with the objective of reducing gastric irritation and increasing potency. Here we describe a series of 4- and 5-heterocyclic salicylic acids and their antiinflammatory-analgesic potencies measured in comparison to aspirin. An improvement of the therapeutic index over aspirin of 100 was achieved; however, the heterocyclic salicylic acids lacked antipyretic activity. Some physicochemical parameters which may bear on the antiinflammatory activity of these compounds are discussed.